Detalles del proyecto
| Estado | Finalizado |
|---|---|
| Fecha de inicio/Fecha fin | 11/2/20 → 7/26/26 |
Financiación
- PDS Biotechnology: 175.199,00 US$
A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK -RDOTAP/HPV-16 E6 & E7 Peptides) and Pembrolizumab (KEYTRUDA) Combination Immunotherapy as a First Line Treatment in Subjects with Recurrent
- Arnold, Susanne M (PI)
- Kejner, Alexandra (Former PI)
- Zinner, Ralph (Former PI)